IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
Wu, Meng; Wang, Xiaopei; Xie, Yan; Liu, Weiping; Zhang, Chen; Ping, Lingyan; Ying, Zhitao; Deng, Lijuan; Zheng, Wen; Lin, Ningjing; Tu, Meifeng; Song, Yuqin; Zhu, Jun
通讯作者Zhu, Jun(1)
关键词Peripheral T-cell lymphomas High dose chemotherapy Autologous peripheral blood stem cell transplantation Retrospective study
刊名INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
2018
DOI10.7150/ijms.23067
15期:9页:867-874
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]MARROW TRANSPLANTATION ; CLASSIFICATION ; CHEMOTHERAPY ; EXPERIENCE ; SURVIVAL ; TRIALS ; NASAL
英文摘要

Background: For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy from conventional chemotherapy. While not all PTCLs could have benefit in survival from HDT/ASCT. The aim of this study was to evaluate the value of high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) in Chinese patients with Peripheral T-cell Lymphomas (PTCLs), in order to determine the cohort most suitable to receive HDT/ASCT.

Methods: A total of 79 patients with PTCLs who received HDT/ASCT in Peking University Cancer Hospital & Institute from January 2001 to august 2016 were retrospectively analyzed.

Results: At a median follow-up time of 23.6 months, the 2-year progression-free survival (PFS) and 2-year overall survival (OS) of the entire cohort were 75.2% and 83.6% respectively. Patients with first complete remission (CR1) (2-year PFS 85.8%, 2-year OS 94.2%) were superior to others in survival. Patients with second complete remission (CR2) had no advantage in survival compared with those with first partial remission (PR1) (2-year PFS: 43.8% vs. 76.2%, p=0.128; 2-year OS: 72.9% vs. 77.1%, p=0.842). In multivariate analysis, response before HDT/ASCT (p=0.001) and LDH before HDT/ASCT (p=0.047) were highly predictive for PFS, while no factors could independently predict OS. Subgroup analysis revealed that HDT/ASCT could improve the survival of patients with angioimmunoblastic T-cell lymphoma (AITL), especially in patients with chemosensitivity. Patients with natural killer / T-cell lymphoma (NKTCL) who received HDT/ASCT with CR1 also had benefit in survival from HDT/ASCT, while nearly 90% of non-CR1 patients appeared bone marrow involvement after HDT/ASCT.

Conclusion: Patients who achieved complete remission after first-line therapy, especially with AITL and NKTCL, should strongly be recommended to receive HDT/ASCT. The future prospective trial is warranted.

语种英语
WOS记录号WOS:000438268100001
通讯作者邮箱zhu-jun2017@outlook.com
第一作者单位Peking Univ, Dept Lymphoma, Minist Educ, Canc Hosp & Inst,Key Lab Carcinogenesis & Transla, Beijing, Peoples R China
通讯作者单位Peking Univ, Dept Lymphoma, Minist Educ, Canc Hosp & Inst,Key Lab Carcinogenesis & Transla, Beijing, Peoples R China
ISSN1449-1907
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142614
专题北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位Peking Univ, Dept Lymphoma, Minist Educ, Canc Hosp & Inst,Key Lab Carcinogenesis & Transla, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Wu, Meng,Wang, Xiaopei,Xie, Yan,et al. Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas[J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES,2018,15(9):867-874.
APA Wu, Meng.,Wang, Xiaopei.,Xie, Yan.,Liu, Weiping.,Zhang, Chen.,...&Zhu, Jun.(2018).Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas.INTERNATIONAL JOURNAL OF MEDICAL SCIENCES,15(9),867-874.
MLA Wu, Meng,et al."Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas".INTERNATIONAL JOURNAL OF MEDICAL SCIENCES 15.9(2018):867-874.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Meng]的文章
[Wang, Xiaopei]的文章
[Xie, Yan]的文章
百度学术
百度学术中相似的文章
[Wu, Meng]的文章
[Wang, Xiaopei]的文章
[Xie, Yan]的文章
必应学术
必应学术中相似的文章
[Wu, Meng]的文章
[Wang, Xiaopei]的文章
[Xie, Yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。